Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Aficamten in Healthy Chinese Adults
NCT04783766Phase 1Completed
- Sponsor
- CORXEL Pharmaceuticals
- Start
- Apr 2021
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of aficamten in hypertrophic cardiomyopathy (HCM) (4 arms), sponsored by CORXEL Pharmaceuticals. Primary endpoints: Subject incidence of Adverse Event (AE), Serious Adverse Event (SAE) and Reduced Left Ventricular Ejection Fraction (LVEF). Started Apr 2021; status: completed.
02
Drugs
aficamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT04783766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04783766.